|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of αvβ3 and CD13 in tumors were checked via immunochemical staining.
|
31829615 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
After the treatment period, the tumor tissues were weighed and harvested for mRNA and protein isolation. qPCR and Western blotting were used to evaluate the expression of cancer stemness markers (epithelial cell adhesion molecule [EpCAM], cluster of differentiation [CD13], CD90, aldehyde dehydrogenase 1 [ALDH1], CD44, and CD45), totipotency factors (sex determining region Y-box 2 [Sox2], Nanog, and octamer-binding transcription factor 4 [Oct4]), and genes involved in the Notch, Wnt/<i>β</i>-catenin, Hedgehog, and Hippo signaling pathways.
|
31341493 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It is expected that the RGD peptide selectively binds to α<sub>v</sub> -integrin receptors, which are highly expressed in cancer cells, and that the NGR peptide selectively targets aminopeptidase N (APN/CD13, EC 3.4.11.2), which is overexpressed in blood vessels of tumors.
|
31318093 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nevertheless, results indicated that both conjugates showed significant effect on inhibition of proliferation in the primary tumor and also on blood vessel formation making them a potential candidate for targeting angiogenesis processes in tumors where CD13 and integrins are involved.
|
31820302 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this proof-of-principle study, we assessed the biological effects of Bestatin on individual cells from different AML cell lines expressing CD13 proteins, a potential target for tumor targeted therapy.
|
30623954 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Peptides containing the asparagine-glycine-arginine (NGR) motif can target the tumor neovascular biomarker CD13/aminopeptidase N receptor.
|
30931855 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We treated adiponectin (APN) knock-out mice with the carcinogen diethylnitrosamine, and the resulting tumors were 7-fold larger than wild-type controls.
|
30794695 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>In situ</i> imaging of aminopeptidase N activity in hepatocellular carcinoma: a migration model for tumour using an activatable two-photon NIR fluorescent probe.
|
30842824 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Truncated tissue factor (tTF)-NGR consists of the extracellular domain of the human TF and the binding motif NGR. tTF-NGR activates blood coagulation within the tumour vasculature following binding to CD13, and is overexpressed in the endothelial cells of tumour vessels, resulting in tumour vessel infarction and subsequent retardation/regression of tumour growth.
|
30655764 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been demonstrated that APN is drastically decreased in obese individuals and that it can play a crucial role in tumor growth.
|
31212761 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several recent preclinical cancer imaging studies have shown that multivalent APN probes exhibit enhanced tumor specificity and accumulation compared to monovalent analogues.
|
30046296 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.
|
30125801 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
From these findings, we propose tCoa-NGR mediated tumor infarction as a novel and promising anti-cancer strategy targeting both CD13 and integrin α<sub>v</sub>β<sub>3</sub> positive tumor neovasculature.
|
29662195 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has the ability to target aminopeptidase N (CD13) on tumor cells or the tumor vascular endothelium.
|
30108463 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, the antitumour and antiangiogenic effects of MT95-4, a fully humanised anti-APN/CD13 monoclonal antibody, were evaluated in mice orthotopically implanted with EHMES-10 (abundantly expressing APN/CD13) and MSTO-211H (scarcely expressing APN/CD13) MPM cells.High tumour APN/CD13 expression was associated with poor prognosis in MPM patients (p=0.04), and MT95-4 treatment reduced tumour growth and angiogenesis in mice harbouring EHMES-10 but not MSTO-211H cells.
|
29519924 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No significant association of CD13 with overall or disease free survival in B cell neoplasms was seen.
|
30066366 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD13 expression in tumor endothelial and vessel associated stromal cells was found in 15% of the investigated samples, while expression in tumor cells was observed in 7%.
|
28604784 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By flow cytometry, both normal and tumor CR cells expressed basal, luminal, and stem cell markers, with the majority of the normal and tumor CR cells expressing prostate basal cell markers, CD44 and Trop2, as well as luminal marker, CD13, suggesting a transit-amplifying phenotype.
|
28009986 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In 52% of the investigated SCLC tissue samples, CD13 was expressed in tumor stroma cells, while the tumor cells were negative for CD13.
|
29110838 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Small drugs that bind to the APN active site inhibit catalysis and suppress tumor growth.
|
28393915 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, decreased APN serum levels are linked with tumor development and progression and inversely associated with markers of inflammation.
|
28529612 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Being peritumoral EpCAM positive was also significantly associated with a larger tumor size, liver cirrhosis, and more frequent vascular invasion; however, no statistically significant association was observed between CD13 and any clinicopathological features.
|
28572700 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Peptides binding to CD13 and RGD-binding integrins provide tumor-homing, which can be exploited for dual targeted delivery of anticancer drugs.
|
28575020 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, LN-functionalized liposomes (LN-LS) could achieve efficient nano-encapsulated drug delivery under APN-overexpressing tumor conditions in vitro and in vivo.
|
28138675 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously it was shown that the recombinant EGFR/CD13 bi-targeted fusion protein ER(Fv)‑LDP-NGR which consists of an anti‑EGFR scFv antibody fragment, a tri‑cyclic NGR peptide, and a lidamycin-derived apoprotein, inhibited the proliferation of cancer cells and markedly suppressed tumor growth of breast carcinoma MCF-7 xenografts in athymic mice.
|
29130101 |
2017 |